Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Receivables (2016 - 2019)

Historic Change in Receivables for Theravance Biopharma (TBPH) over the last 7 years, with Q4 2019 value amounting to -$86000.0.

  • Theravance Biopharma's Change in Receivables rose 9642.26% to -$86000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was -$620000.0, marking a year-over-year increase of 6203.31%. This contributed to the annual value of -$620000.0 for FY2019, which is 6203.31% up from last year.
  • As of Q4 2019, Theravance Biopharma's Change in Receivables stood at -$86000.0, which was up 9642.26% from -$145000.0 recorded in Q3 2019.
  • Theravance Biopharma's 5-year Change in Receivables high stood at $1.5 million for Q2 2018, and its period low was -$2.4 million during Q4 2018.
  • Its 5-year average for Change in Receivables is -$14450.0, with a median of $45500.0 in 2015.
  • In the last 5 years, Theravance Biopharma's Change in Receivables plummeted by 436818.18% in 2016 and then soared by 119292.04% in 2018.
  • Over the past 5 years, Theravance Biopharma's Change in Receivables (Quarter) stood at $1.1 million in 2015, then crashed by 119.93% to -$227000.0 in 2016, then soared by 398.24% to $677000.0 in 2017, then tumbled by 455.1% to -$2.4 million in 2018, then skyrocketed by 96.42% to -$86000.0 in 2019.
  • Its last three reported values are -$86000.0 in Q4 2019, -$145000.0 for Q3 2019, and $118000.0 during Q2 2019.